Entero Therapeutics Announces Reverse Stock Split

Entero Therapeutics ( (ENTO) ) just unveiled an update.

Entero Therapeutics, Inc. announced a 1-for-3 reverse stock split of its common stock, approved by the board and shareholders on June 30, 2025, and effective on August 18, 2025. This move aims to increase the per-share bid price above $1.00 to comply with Nasdaq’s listing requirements, thereby maintaining its listing on the Nasdaq Capital Market. The reverse stock split will reduce the company’s outstanding common stock from approximately 4.77 million shares to about 1.59 million shares, and stockholders will receive cash for fractional shares. The company emphasizes the importance of maintaining Nasdaq listing for enhancing shareholder value.

More about Entero Therapeutics

Entero Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company is working on Adrulipase, a recombinant lipase enzyme aimed at aiding digestion in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Average Trading Volume: 6,619,177

Technical Sentiment Signal: Sell

Current Market Cap: $2.92M

See more insights into ENTO stock on TipRanks’ Stock Analysis page.